Bicycle Therapeutics plc (BCYC): Business Model Canvas [Apr-2026 Updated]

You're trying to figure out if Bicycle Therapeutics plc is a platform play or a pipeline story, and honestly, it's both, but the clock is ticking on that cash. As an analyst who's seen this movie before, the story here isn't just the novel Bicyclic Peptide technology; it's how they are monetizing it now to fund the next big thing. With $648.3 million in the bank as of September 30, 2025, they have runway, but Q2 R&D spend hit $71.0 million pushing their lead asset, zelenectide pevedotin, through late-stage trials. The whole model hinges on those high-value partnerships with giants like Genentech and Merck keeping the engine running while they prove out the science-it's a classic biotech high-wire act. Check out the full canvas below to see the exact structure supporting this high-stakes execution; Finance: draft the 13-week cash view based on these Q3 numbers by Friday.

Bicycle Therapeutics plc (BCYC) - Canvas Business Model: Key Partnerships

You're looking at the core of Bicycle Therapeutics plc's (BCYC) external value creation engine-the Key Partnerships block. This is where the heavy lifting of clinical development and commercialization risk is shared, and it's where a significant portion of their non-dilutive funding comes from. Honestly, for a clinical-stage biotech, these deals are the lifeblood.

Bicycle Therapeutics plc finances its operations primarily with proceeds received from upfront payments, research and development payments, and development milestone payments from these collaboration agreements. As of the second quarter of 2025, the company reported cash and cash equivalents of $721.5 million as of June 30, 2025, with an expected financial runway extending into 2028, largely supported by these external funding mechanisms.

The structure of these alliances is designed to capture value across the entire development spectrum, from early discovery through to commercial sales. The prompt mentioned potential milestones up to $1.7 billion; this figure is specifically tied to the strategic collaboration with Novartis for Bicycle Radio-Conjugates (BRCs).

Here's a breakdown of the publicly detailed financial structures with major pharmaceutical entities:

The Genentech deal, initiated in February 2020, is structured for up to four potential development candidates against multiple immuno-oncology targets. For each collaboration program under that agreement, Bicycle Therapeutics plc is eligible for:

• Additional development milestones totaling up to $65.0 million.
• Regulatory milestones of up to $135.0 million.
• Sales milestone payments up to $200.0 million on a program-by-program basis.

The Novartis agreement involves a tiered royalty structure on net sales of commercialized Bicycle-based medicines, in addition to the upfront payment and milestones. For the Novartis collaboration, milestone payments are structured such that for each target, Bicycle Therapeutics plc is eligible for additional development and regulatory/first commercial sale milestones of up to $210.0 million for the first radionuclide product and the same amount for the non-radionuclide product, totaling up to $840.0 million in aggregate for both product types across the targets.

Bicycle Therapeutics plc also maintains relationships with other key players, though specific 2025 financial terms aren't always public in the same detail. The company works closely with its key collaborators, including Bayer, Novartis, Ionis, and Genentech. The prompt specifically mentioned Alexion AstraZeneca Rare Disease for non-oncology applications; while the company is exploring the use of Bicycle technology for diseases beyond oncology through various partnerships, specific financial details for an Alexion AstraZeneca Rare Disease deal aren't detailed in the latest reports found.

For operational execution, like clinical trial management, the reliance on Contract Research Organizations (CROs) is standard practice. While the prompt mentioned IQVIA, the company's R&D expenses for the three months ended September 30, 2025, were $58.4 million, an increase from the prior year, primarily due to increased clinical program expenses for zelenectide pevedotin development. This increased activity implies ongoing engagement with external service providers, including CROs. Similarly, engaging academic institutions for early-stage drug discovery and research is a common practice, as evidenced by the ongoing clinical trial sponsored by Cancer Research UK (CRUK) for BT1718, which has a separate agreement structure involving milestone payments up to $50.9 million plus royalties.

You'll want to track the R&D tax credits as well, as they impact the net cost of these external activities; Bicycle Therapeutics plc received net proceeds of $544.1 million from a private placement in May 2024, and in October 2025, they received $38.2 million related to their U.K. R&D tax credit claim for the year ended December 31, 2024.

Finance: draft 13-week cash view by Friday.

Bicycle Therapeutics plc (BCYC) - Canvas Business Model: Key Activities

You're looking at the core engine of Bicycle Therapeutics plc-the activities that consume capital and drive potential value creation. Honestly, for a clinical-stage biotech, this is where the rubber meets the road, and the numbers tell a clear story of heavy investment in the lead candidate.

Research and development (R&D) of proprietary Bicycle® molecules.

The fundamental activity is the ongoing research and development using the proprietary bicyclic peptide (Bicycle®) technology platform. This platform is used to screen quadrillions of potential molecules to identify candidates with high affinity and selectivity.

Financial commitment to this core activity is substantial. For the three months ended June 30, 2025, Research and development (R&D) expenses were reported at $71.0 million. This was an increase from the $40.1 million reported for the same period in 2024, primarily driven by increased clinical program expenses for zelenectide pevedotin development. To be fair, the Q1 2025 R&D expense was slightly lower at $59.1 million for the quarter ended March 31, 2025.

Key operational metrics related to the pipeline and financials as of late 2025 include:

Advancing lead Bicycle Drug Conjugate (BDC) zelenectide pevedotin in Phase 2/3 trials.

Advancing zelenectide pevedotin, a Bicycle Drug Conjugate (BDC) targeting Nectin-4, is a primary focus. This involves managing multiple ongoing trials across different indications, leveraging the NECTIN4 gene amplification strategy.

The key activities here revolve around the Duravelo trials:

• Managing the Phase 2/3 Duravelo-2 registrational trial for metastatic urothelial cancer (mUC) in combination with pembrolizumab (Cohort 1) and as monotherapy/combination (Cohort 2).
• Executing the Phase 1/2 Duravelo-3 trial for NECTIN4-amplified breast cancer, which was initiated in the first half of 2025.
• Executing the Phase 1/2 Duravelo-4 trial for NECTIN4-amplified non-small cell lung cancer (NSCLC), initiated in the second half of 2025.
• Seeking regulatory feedback to make an informed decision on the path forward for mUC, with dose selection and approval pathway updates expected in the first quarter of 2026.

The company is actively enrolling patients across these global oncology trials.

Developing the emerging Bicycle Radioconjugate (BRC) pipeline.

A critical activity is progressing the emerging Bicycle Radioconjugate (BRC) pipeline to establish leadership in next-generation radiopharmaceuticals. This involves translating preclinical validation into human data.

Specific BRC development activities include:

• Presenting human imaging data for the BRC molecule targeting MT1-MMP at the European Association for Nuclear Medicine (EANM) 2025 Congress.
• Generating initial human imaging data for the second BRC target, EphA2, expected in the second half of 2025.
• Planning the initiation of the first company-sponsored BRC clinical trials for 2026.

The imaging data for MT1-MMP were representative of data generated to date in 12 out of 14 patients with various solid tumors.

Managing and executing global oncology clinical trials (Duravelo-2, -3, -4).

This activity is the logistical backbone supporting the advancement of zelenectide pevedotin. It requires managing complex, multi-center, international operations.

The scale of execution is significant:

• The Duravelo-2 trial expanded to include approximately 170 active sites across 20 countries as of mid-2025.
• The company is managing dose selection from Duravelo-2 based on data from approximately 150 patients across treatment arms.
• The company is also managing the initiation and enrollment of the Duravelo-3 (breast cancer) and Duravelo-4 (NSCLC) trials during 2025.

Clinical trial execution is directly tied to the R&D expense figures you see.

Protecting and expanding the core intellectual property (IP) portfolio.

Protecting the core technology is non-negotiable; it's the moat around the business. This activity focuses on securing and expanding patent families related to the platform and product candidates.

As of December 31, 2024, the intellectual property portfolio was structured with substantial coverage:

• 48 patent families directed to bicyclic peptides and related conjugates.
• 21 patent families directed to later inventions, such as methods of use.
• 10 patent families directed to novel scaffolds, linkers, and payloads.
• 10 patent families directed to the platform technology itself.

This robust patent estate underpins the long-term value of Bicycle Therapeutics plc.

Bicycle Therapeutics plc (BCYC) - Canvas Business Model: Key Resources

You're building a biotech company, and the most critical assets aren't always on the balance sheet, but for Bicycle Therapeutics plc (BCYC), the financial foundation is certainly a key resource right now. As of September 30, 2025, the company held $648.3 million in cash and cash equivalents. That's a solid war chest, especially considering they also received a $38.2 million U.K. R&D tax credit in October 2025. Here's the quick math: that cash position, plus the tax credit, gives them an expected financial runway extending into 2028. That runway is what funds the development of their core technology and pipeline assets. Still, remember that R&D expenses for the three months ended September 30, 2025, were $58.4 million, so that cash is being deployed actively.

The absolute bedrock of Bicycle Therapeutics plc's value is its Proprietary Bicyclic Peptide (Bicycle®) technology platform. This isn't just a buzzword; it's a fully synthetic short peptide constrained with a small molecule scaffold to create two loops. This structure is designed to achieve the high affinity and selectivity of biologics while maintaining the favorable tissue-penetration properties of small molecules. This platform is the engine driving all their drug candidates.

The intellectual property (IP) surrounding this platform is a massive intangible resource. You're looking at extensive IP covering the Bicycle molecule scaffold and drug candidates. This proprietary position is what creates the barrier to entry for competitors trying to replicate their approach. Furthermore, the company has built out its human capital, relying on specialized scientific and clinical development personnel, recently bolstered by appointments to the Board of Directors and the Research and Innovation Advisory Board to further strengthen strategic growth.

The tangible value of these resources is best seen in the clinical pipeline. You need to track the progress of these assets closely, as they represent the near-term value drivers. Here is a snapshot of the key clinical-stage assets as of late 2025:

• Zelenectide pevedotin (Nectin-4 targeting BDC) in metastatic urothelial cancer (mUC) via the Phase 2/3 Duravelo-2 trial.
• Zelenectide pevedotin in NECTIN4-amplified breast cancer via the Phase 1/2 Duravelo-3 trial.
• Zelenectide pevedotin in NECTIN4-amplified non-small cell lung cancer via the Phase 1/2 Duravelo-4 trial.
• BT5528, targeting EphA2, in a company-sponsored Phase I/II clinical trial.
• BT7480, a Bicycle TICA molecule targeting Nectin-4 and agonising CD137, in a company-sponsored Phase I/II clinical trial.

To give you a clearer picture of the financial context supporting these key resources, here is a look at the Q3 2025 performance, which directly impacts the cash burn rate:

What this estimate hides is the operational cash flow; in the last 12 months leading up to September 30, 2025, the operating cash flow was negative at -$239.73 million, resulting in a free cash flow of -$241.87 million. That's the burn you are funding with that cash balance. Finance: draft 13-week cash view by Friday.

Bicycle Therapeutics plc (BCYC) - Canvas Business Model: Value Propositions

You're looking at the core value Bicycle Therapeutics plc (BCYC) brings to the table, which is all about their proprietary platform. This isn't just another drug class; it's a synthetic short peptide constrained to form two loops, which gives it a unique profile. This technology is designed to deliver the high binding specificity you see with biologics but with the favorable tissue-penetration properties of small molecules. This structural constraint is key to their value proposition.

The financial backing supporting this development as of late 2025 shows significant investment in this novel approach, primarily focused on oncology indications where existing treatments fall short. For instance, Q3 2025 revenue came in at $11.73 million, beating the consensus estimate of $8.25 million. The company reported cash and cash equivalents of $648.3 million as of September 30, 2025. This balance sheet strength, bolstered by a $38.2 million U.K. R&D tax credit received in October 2025, provides an expected financial runway extending into 2028. Still, R&D expenses for the third quarter of 2025 were $58.4 million, reflecting the cost of advancing this pipeline.

The platform's ability to target historically undruggable targets is a major value driver, exemplified by BT5528, a Bicycle Toxin Conjugate (BTC) targeting EphA2. This target has been difficult for prior antibody drug conjugate (ADC) approaches due to toxicity concerns. The clinical data for BT5528 suggests a differentiated safety profile; for instance, it was not associated with the bleeding events seen with other EphA2 therapies. The Recommended Phase II Dose (RP2D) selected was 6.5 mg/m2 administered once every 2 weeks. At this RP2D, the overall response rate (ORR) was reported as 6.7%. Earlier data showed ORRs of 22% in EphA2-positive ovarian cancer and 67% in urothelial cancer patients.

Precision-guided delivery is inherent in the design, allowing for the targeted delivery of various payloads, including toxins and radionuclides. This is where the physical properties of the Bicycle molecule really shine. Here's a quick look at the physical advantages supporting this precision:

• Bicycle molecules combine the binding specificity of biologics with the tissue-penetration properties of small molecules.
• Preclinical data support rapid tumor penetration for Bicycle molecules.
• Preclinical data also show rapid renal elimination for Bicycle Radionuclide Conjugates (BRCs).
• The BT5528 molecule itself has a short half-life of 0.4-0.7 hours.
• The technology allows for the development of Bicycle® Radioconjugates (BRC®) using a stable linker-chelator system and a potent radioisotope.

The focus remains on oncology, addressing diseases underserved by current options. For example, the lead candidate, zelenectide pevedotin, is being evaluated in the Phase 2/3 Duravelo-2 trial for metastatic urothelial cancer (mUC). Furthermore, the pipeline includes trials for NECTIN4-amplified breast cancer (Duravelo-3) and non-small cell lung cancer (Duravelo-4). The company is also advancing BT7480, a Bicycle TICA molecule targeting Nectin-4 and agonizing CD137. You'll want to watch for the dose selection update from the Duravelo-2 trial, which management pushed to Q1 2026. Finance: draft 13-week cash view by Friday.

Bicycle Therapeutics plc (BCYC) - Canvas Business Model: Customer Relationships

You're looking at how Bicycle Therapeutics plc (BCYC) manages its key external relationships, which are crucial for funding development and advancing its pipeline. For a clinical-stage company, these relationships-partners, regulators, and investors-are the lifeblood.

High-touch, long-term strategic alliances with pharmaceutical partners

Bicycle Therapeutics plc relies heavily on strategic alliances to fund and expand development outside its core oncology focus. These are not simple transactions; they involve deep, ongoing collaboration to advance novel medicines. The value locked in these relationships is substantial, even if the revenue is milestone-based rather than from product sales.

For instance, the collaboration with Novartis includes potential development and commercial-based milestone payments totaling up to \$1.7 billion for a single target, contingent on success for both radionuclide and non-radionuclide product types, with an aggregate potential of up to \$840.0 million across all targets for the latter type. The upfront payment received from Novartis was \$50 million. The agreement with Bayer has potential milestones up to £178.3 million (or \$223.8 million) for the first product for a target, or up to \$534.9 million (or \$671.3 million) across all three potential target programs.

By the end of 2024, Bicycle Therapeutics plc had received a total of \$236.6 million in cash payments from its collaboration agreements, which included \$45.3 million from Bayer, \$53.0 million from Novartis, \$47.7 million from Ionis, and \$56.0 million from Genentech. The agreement with Cancer Research Technology Limited (CRUK) also outlines future milestone payments aggregating \$50.9 million, plus royalties based on a single-digit percentage of net sales.

Here's a look at the financial commitment from key partners as of the end of 2024:

These relationships are designed to be long-term, leveraging collaborators' deep expertise outside of Bicycle Therapeutics plc's internal focus areas like oncology.

Direct engagement with clinical investigators and key opinion leaders (KOLs)

Direct engagement is focused on advancing the internal pipeline through clinical execution and strengthening scientific direction. This involves managing ongoing trials and integrating external expertise into the company's strategy.

The company is actively enrolling patients in multiple company-sponsored trials as of late 2025:

• Phase 1/2 Duravelo-3 trial for zelenectide pevedotin in NECTIN4-amplified breast cancer.
• Phase 1/2 Duravelo-4 trial for zelenectide pevedotin in NECTIN4-amplified non-small cell lung cancer.
• Phase I/II trial for BT5528 targeting EphA2.
• Phase I/II trial for BT7480 targeting Nectin-4 and agonizing CD137.

To further strengthen innovation, Bicycle Therapeutics plc welcomed new esteemed global oncology leaders to its Board of Directors and its Research and Innovation Advisory Board during 2025. This infusion of external KOL expertise helps guide the development path for candidates like zelenectide pevedotin, BT5528, and BT7480.

Investor relations and public disclosures for capital market confidence

Maintaining confidence with the capital markets is vital, as the company finances operations primarily through share sales and collaboration payments. The company provided regular updates to investors throughout 2025, including financial results presentations.

Key financial metrics reported in 2025 demonstrate the cash runway supporting these relationships:

• Cash and cash equivalents were \$793.0 million as of March 31, 2025.
• Cash and cash equivalents were \$721.5 million as of June 30, 2025.
• Cash and cash equivalents were \$648.3 million as of September 30, 2025.

The expected financial runway extends into 2028, based on the Q3 2025 figures. This financial stability is underpinned by total gross proceeds of \$1.4 billion from share sales from inception through December 31, 2024. Public disclosures included reporting Q2 2025 results on August 8, 2025, and Q3 2025 results on October 30, 2025.

Regulatory agency interactions for clinical trial approvals and pathway decisions

Interactions with regulatory bodies directly impact the timeline and commercial viability of the lead assets. Bicycle Therapeutics plc is actively engaged with agencies regarding its most advanced program.

For zelenectide pevedotin in metastatic urothelial cancer (mUC), the company is currently seeking broad regulatory feedback. Bicycle Therapeutics plc expects to provide an update on dose selection for the Phase 2/3 Duravelo-2 trial and the potential accelerated approval pathway following meetings with multiple regulatory agencies in the first quarter of 2026. Furthermore, combination data for BT5528 and BT7480 with nivolumab are anticipated to be presented at scientific conferences in the first half of 2026.

The company's engagement also involves presenting data at key medical congresses, such as the European Association of Nuclear Medicine (EANM) 2025 Congress, which featured data on an early Bicycle Imaging Agent (BIA) targeting MT1-MMP.

Bicycle Therapeutics plc (BCYC) - Canvas Business Model: Channels

You're looking at how Bicycle Therapeutics plc gets its science and its financial story out to the world, which is key for a clinical-stage biotech. It's a mix of scientific validation and capital markets engagement.

Direct engagement with pharmaceutical and biotech companies for out-licensing

Direct engagement is about proving the platform works so partners will invest in the pipeline through deals. Bicycle Therapeutics plc has existing collaborations, for instance, with Novartis and Bayer, which are channels for technology validation and revenue generation. The company reported collaboration revenues of $2.9 million in the second quarter of 2025. This channel is managed by the business development team, which has supported several transactions.

• Leveraging proprietary bicyclic peptide (Bicycle®) technology.
• Seeking to drive early revenue through licensing arrangements.

Scientific publications and presentations at major oncology conferences (ASCO, AACR)

Getting data in front of the scientific community is a primary channel for establishing credibility. Bicycle Therapeutics plc had multiple abstracts accepted for presentation at the 2025 ASCO and AACR annual meetings, showing the breadth of the Bicycle® technology. Furthermore, data for an early Bicycle® Radioconjugate (BRC®) molecule targeting MT1-MMP was presented at the European Association of Nuclear Medicine (EANM) 2025 Congress. Trial in Progress data for the Duravelo-3 trial was also presented at the European Society for Medical Oncology (ESMO) Congress 2025. This scientific dissemination is crucial for future partnership discussions.

Clinical trial sites (hospitals, cancer centers) for patient enrollment

The clinical trials themselves are a massive channel for generating the data needed for regulatory approval and commercial viability. The Duravelo-2 trial, focusing on zelenectide pevedotin in metastatic urothelial cancer (mUC), has expanded to include approximately 170 active sites across 20 countries. Analysts anticipated dose selection for this pivotal trial by the end of 2025, based on data from roughly 150 patients across various treatment arms. The company also has other trials actively enrolling patients, such as Duravelo-3 in breast cancer and Duravelo-4 in non-small cell lung cancer (NSCLC).

Here's a quick look at some operational metrics related to these channels as of mid-to-late 2025:

Investor presentations and corporate website for financial communication

Communicating financial health and pipeline progress to the investment community is a non-stop channel. Bicycle Therapeutics plc management participated in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference on May 20, 2025. The corporate website, www.bicycletherapeutics.com, serves as the archive for webcasts and press releases, such as the one detailing third-quarter 2025 financial results on October 30, 2025. The company's cash position as of September 30, 2025, was $648.3 million, with an expected financial runway extending into 2028. This runway is a key piece of information delivered through this channel. You can find investor contacts like Stephanie Yao for direct inquiries.

The company is definitely focused on hitting those key milestones to maintain investor confidence.

Bicycle Therapeutics plc (BCYC) - Canvas Business Model: Customer Segments

You're looking at the core groups Bicycle Therapeutics plc (BCYC) targets with its novel bicyclic peptide technology, and the numbers that define those relationships as of late 2025.

Large pharmaceutical and biotechnology companies seeking novel drug platforms are key partners for advancing the pipeline beyond internal focus areas and securing non-dilutive funding through milestone payments and upfront fees. These relationships validate the platform's broad applicability.

Oncologists and clinicians treating advanced solid tumors are the prescribers who will ultimately use the approved Bicycle Therapeutics plc (BCYC) medicines. Their adoption hinges on clinical efficacy data, such as the 65% overall response rate (ORR) seen with zelenectide pevedotin plus pembrolizumab in a cohort of first-line cisplatin-ineligible metastatic urothelial cancer (mUC) patients as of January 3, 2025. Clinicians are also tracking data for other indications, like the 57.1% ORR observed in triple-negative breast cancer (TNBC) patients with NECTIN4 amplification/polysomy.

Cancer patients with high unmet medical need, particularly Nectin-4 amplified tumors, are the ultimate beneficiaries. The development strategy is explicitly leveraging NECTIN4 gene amplification across breast cancer, lung cancer, and multiple tumor types. The company has Phase 1/2 trials open and actively enrolling for NECTIN4-amplified non-small cell lung cancer (Duravelo-4) and NECTIN4-amplified breast cancer (Duravelo-3).

Institutional and retail investors funding high-risk, high-reward biotech R&D are essential for maintaining the operational runway to reach clinical milestones. The company reported Cash and cash equivalents of $721.5 million as of June 30, 2025, which, following a strategic cost realignment of approximately 30%, was expected to extend the financial runway into 2028.

Here's a quick look at the financial metrics relevant to the investor segment as of late 2025:

The clinical focus areas and associated patient stratification data define the immediate target patient pool for Bicycle Therapeutics plc (BCYC) assets:

• Phase 2/3 Duravelo-2 registrational trial for mUC is ongoing, with dose selection data anticipated in 4Q 2025.
• Zelenectide pevedotin monotherapy showed 45% ORR in late-line mUC patients not previously treated with enfortumab vedotin.
• Phase 1/2 trials for NECTIN4-amplified breast cancer (Duravelo-3) and lung cancer (Duravelo-4) are open and actively enrolling.
• Initial EphA2 human imaging data for the BRC pipeline is expected in 2H 2025.
• Company-sponsored clinical trials for the BRC pipeline are planned to start in 2026.
• BT7480 (Nectin-4 targeted CD137 agonist) combination data with nivolumab is expected in 1H 2026.

The company's technology platform is also being explored in other indications, evidenced by imaging data from 12 out of 14 patients with various solid tumors related to the MT1-MMP BRC molecule.

Bicycle Therapeutics plc (BCYC) - Canvas Business Model: Cost Structure

You're looking at the cost side of Bicycle Therapeutics plc's operations as of late 2025, which is heavily weighted toward research and development, as is typical for a clinical-stage biotech. The primary cost driver is the advancement of their pipeline, especially zelenectide pevedotin.

Research and development (R&D) expenses were reported at $71.0 million for the three months ended June 30, 2025. This significant spend reflects the costs associated with ongoing clinical trials and discovery work on their Bicycle Drug Conjugates and Radioconjugates. To give you a snapshot of the financial footing supporting these costs, cash and cash equivalents stood at $648.3 million as of September 30, 2025, though this was down from $721.5 million at the end of Q2 2025.

Here's a look at some key financial metrics from the Q2 2025 period:

Personnel costs are definitely a major component within that R&D figure. The increase in R&D expense from the prior year was explicitly noted as being due in part to increased personnel-related costs for the specialized scientific and clinical staff needed to run trials like Duravelo-1 and Duravelo-2. You can't develop novel therapeutics without top-tier talent; it's a necessary, high-cost input.

General and administrative (G&A) overhead was $18.5 million for the second quarter of 2025. This covers the operational backbone-finance, HR, executive functions, and the infrastructure supporting the science, which is distinct from the direct clinical trial spending.

To manage burn rate and extend runway, Bicycle Therapeutics plc implemented significant structural changes:

• Strategic cost realignment efforts targeting approximately 30% operational savings.
• These efforts were primarily executed through a workforce reduction, affecting around 25% of staff.
• Severance payments and related charges for this restructuring totaled $5.3 million, mostly booked in Q3 2025.

Finally, you have the ongoing, less visible costs of protecting the core technology. This includes Intellectual Property (IP) maintenance and legal costs necessary to secure and defend the global patent protection for their proprietary bicyclic peptide platform. These are fixed, recurring costs essential for maintaining the exclusivity of their value proposition.

Finance: draft 13-week cash view by Friday.

Bicycle Therapeutics plc (BCYC) - Canvas Business Model: Revenue Streams

You're looking at the engine that keeps Bicycle Therapeutics plc running right now, which is almost entirely driven by its strategic pharma alliances. This isn't about product sales yet; it's about the upfront cash and research funding that fuels the pipeline.

The core of Bicycle Therapeutics plc's current top line is Research collaboration revenue from existing pharma partnerships. These agreements, which are the lifeblood of a clinical-stage biotech, bring in non-dilutive capital. As of late 2025, the company's revenue is heavily weighted here, reflecting the progress being made across its pipeline programs with its partners.

The financial snapshot for the trailing twelve months (TTM) ending with the third quarter of 2025 is quite clear. Bicycle Therapeutics plc reported a TTM revenue of approximately $28.34 million, primarily collaboration-based. This is supported by the Q3 2025 revenue figure, which came in at $11.73 million, beating consensus estimates.

Revenue recognition is lumpy, which is typical for this model, coming from Upfront and milestone payments from new and existing licensing agreements. These payments are crucial for funding operations before any drug hits the market. To give you some context on the scale of these deals, since inception through the end of 2024, Bicycle Therapeutics plc had already received $236.6 million in cash payments under its collaboration agreements with partners like Bayer, Novartis, Ionis, and Genentech.

Here's a look at the key revenue drivers and potential streams:

• Research and development services revenue.
• Upfront payments from new agreements.
• Milestone payments tied to clinical progress.
• Option exercise payments received.

The real upside, the part that changes the valuation significantly down the road, lies in Potential future royalties on net sales of commercialized partnered products. While not revenue today, these are the long-term cash flows built into the contracts. For example, under one collaboration program, Bicycle Therapeutics plc is eligible for up to $200.0 million in sales milestone payments on a program-by-program basis with Genentech. Also, for a specific target with Novartis, they are eligible for up to $840.0 million in aggregate milestones if both a radionuclide and a non-radionuclide product are successfully commercialized.

It's also important to note the non-dilutive cash inflow from the government side. Bicycle Therapeutics plc benefits from the U.K. R&D tax credits providing a cash inflow. You saw a significant cash boost in October 2025 with the receipt of $38.2 million from the U.K. R&D tax credit. This regime allows for a cash rebate of up to 26.97% of qualifying expenditure if the company qualifies as R&D intensive, which is a key factor in their cash runway planning.

We can map out the structure of the collaboration revenue sources:

The company explicitly states that future revenue will fluctuate based on the timing and amount of these milestone achievements. Honestly, this is the financial reality of a platform company: lumpy, but with massive potential upside baked into the contracts.

Finance: draft 13-week cash view by Friday.